Haemonetics Corporation (NYSE: HAE) Stock Competitors & Peer Comparison

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, HAE's ROE is +0.11%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, HAE is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for HAE.Check BSX-PA's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, ABT has a market cap of 174.7B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while ABT trades at $100.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas ABT's P/E ratio is 19.38. In terms of profitability, HAE's ROE is +0.11%, compared to ABT's ROE of +0.11%. Regarding short-term risk, HAE is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for HAE.Check ABT's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, MDT has a market cap of 114.5B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while MDT trades at $89.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas MDT's P/E ratio is 16.18. In terms of profitability, HAE's ROE is +0.11%, compared to MDT's ROE of +0.11%. Regarding short-term risk, HAE is less volatile compared to MDT. This indicates lower risk in terms of short-term price fluctuations for HAE.Check MDT's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, SYK has a market cap of 105.6B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while SYK trades at $275.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas SYK's P/E ratio is 20.57. In terms of profitability, HAE's ROE is +0.11%, compared to SYK's ROE of +0.16%. Regarding short-term risk, HAE is less volatile compared to SYK. This indicates lower risk in terms of short-term price fluctuations for HAE.Check SYK's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, BSX has a market cap of 65.6B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while BSX trades at $44.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas BSX's P/E ratio is 14.23. In terms of profitability, HAE's ROE is +0.11%, compared to BSX's ROE of +0.15%. Regarding short-term risk, HAE is less volatile compared to BSX. This indicates lower risk in terms of short-term price fluctuations for HAE.Check BSX's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, EW has a market cap of 50B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while EW trades at $86.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas EW's P/E ratio is 32.16. In terms of profitability, HAE's ROE is +0.11%, compared to EW's ROE of +0.10%. Regarding short-term risk, HAE is less volatile compared to EW. This indicates lower risk in terms of short-term price fluctuations for HAE.Check EW's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, DXCM has a market cap of 32.7B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while DXCM trades at $86.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas DXCM's P/E ratio is 33.99. In terms of profitability, HAE's ROE is +0.11%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, HAE is less volatile compared to DXCM. This indicates lower risk in terms of short-term price fluctuations for HAE.Check DXCM's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, GEHC has a market cap of 30.2B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while GEHC trades at $66.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas GEHC's P/E ratio is 14.64. In terms of profitability, HAE's ROE is +0.11%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, HAE is less volatile compared to GEHC. This indicates lower risk in terms of short-term price fluctuations for HAE.Check GEHC's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, PHG has a market cap of 24.5B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while PHG trades at $25.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas PHG's P/E ratio is 14.35. In terms of profitability, HAE's ROE is +0.11%, compared to PHG's ROE of +0.10%. Regarding short-term risk, HAE is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for HAE.Check PHG's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, ZBH has a market cap of 17.7B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while ZBH trades at $91.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas ZBH's P/E ratio is 10.80. In terms of profitability, HAE's ROE is +0.11%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, HAE is less volatile compared to ZBH. This indicates lower risk in terms of short-term price fluctuations for HAE.Check ZBH's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas ABMD's P/E ratio is 65.36. In terms of profitability, HAE's ROE is +0.11%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, HAE is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for HAE.Check ABMD's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while PEN trades at $319.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas PEN's P/E ratio is 83.31. In terms of profitability, HAE's ROE is +0.11%, compared to PEN's ROE of +0.11%. Regarding short-term risk, HAE is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for HAE.Check PEN's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas SWAV's P/E ratio is 78.76. In terms of profitability, HAE's ROE is +0.11%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, HAE is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for HAE.Check SWAV's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, SNN has a market cap of 11.4B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while SNN trades at $27.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas SNN's P/E ratio is 18.28. In terms of profitability, HAE's ROE is +0.11%, compared to SNN's ROE of +0.12%. Regarding short-term risk, HAE is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for HAE.Check SNN's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, BIO-B has a market cap of 10.5B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while BIO-B trades at $385.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas BIO-B's P/E ratio is -67.89. In terms of profitability, HAE's ROE is +0.11%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, HAE is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for HAE.Check BIO-B's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, ALGN has a market cap of 10.4B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while ALGN trades at $145.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas ALGN's P/E ratio is 13.22. In terms of profitability, HAE's ROE is +0.11%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, HAE is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for HAE.Check ALGN's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, BIO has a market cap of 10.2B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while BIO trades at $377.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas BIO's P/E ratio is 40.70. In terms of profitability, HAE's ROE is +0.11%, compared to BIO's ROE of +0.03%. Regarding short-term risk, HAE is less volatile compared to BIO. This indicates lower risk in terms of short-term price fluctuations for HAE.Check BIO's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, GMED has a market cap of 10.1B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while GMED trades at $74.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas GMED's P/E ratio is 16.84. In terms of profitability, HAE's ROE is +0.11%, compared to GMED's ROE of +0.12%. Regarding short-term risk, HAE is less volatile compared to GMED. This indicates lower risk in terms of short-term price fluctuations for HAE.Check GMED's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, BRKR has a market cap of 9.6B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while BRKR trades at $63.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas BRKR's P/E ratio is 31.80. In terms of profitability, HAE's ROE is +0.11%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, HAE is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for HAE.Check BRKR's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while MASI trades at $179.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas MASI's P/E ratio is 44.43. In terms of profitability, HAE's ROE is +0.11%, compared to MASI's ROE of +0.09%. Regarding short-term risk, HAE is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for HAE.Check MASI's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, GKOS has a market cap of 9.3B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while GKOS trades at $158.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas GKOS's P/E ratio is -184.31. In terms of profitability, HAE's ROE is +0.11%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, HAE is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for HAE.Check GKOS's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, BRKRP has a market cap of 9.3B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while BRKRP trades at $469.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas BRKRP's P/E ratio is 251.76. In terms of profitability, HAE's ROE is +0.11%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, HAE is less volatile compared to BRKRP. This indicates lower risk in terms of short-term price fluctuations for HAE.Check BRKRP's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, PODD has a market cap of 9.2B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while PODD trades at $133.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas PODD's P/E ratio is 22.68. In terms of profitability, HAE's ROE is +0.11%, compared to PODD's ROE of +0.27%. Regarding short-term risk, HAE is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for HAE.Check PODD's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas NARI's P/E ratio is -59.24. In terms of profitability, HAE's ROE is +0.11%, compared to NARI's ROE of -0.00%. Regarding short-term risk, HAE is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for HAE.Check NARI's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while ITGR trades at $126.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas ITGR's P/E ratio is 19.90. In terms of profitability, HAE's ROE is +0.11%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, HAE is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for HAE.Check ITGR's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, LIVN has a market cap of 4.2B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while LIVN trades at $77.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas LIVN's P/E ratio is 18.34. In terms of profitability, HAE's ROE is +0.11%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, HAE is less volatile compared to LIVN. This indicates lower risk in terms of short-term price fluctuations for HAE.Check LIVN's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, IRTC has a market cap of 3.7B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while IRTC trades at $112.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas IRTC's P/E ratio is -261.86. In terms of profitability, HAE's ROE is +0.11%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, HAE is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for HAE.Check IRTC's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas AXNX's P/E ratio is -709.80. In terms of profitability, HAE's ROE is +0.11%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, HAE is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for HAE.Check AXNX's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, NEOG has a market cap of 3B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while NEOG trades at $13.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas NEOG's P/E ratio is 49.00. In terms of profitability, HAE's ROE is +0.11%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, HAE is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for HAE.Check NEOG's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, TMDX has a market cap of 2.9B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while TMDX trades at $82.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas TMDX's P/E ratio is 41.99. In terms of profitability, HAE's ROE is +0.11%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, HAE is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for HAE.Check TMDX's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, BFLY has a market cap of 2.4B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while BFLY trades at $9.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas BFLY's P/E ratio is -38.10. In terms of profitability, HAE's ROE is +0.11%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, HAE is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for HAE.Check BFLY's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, AXGN has a market cap of 2.3B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while AXGN trades at $43.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas AXGN's P/E ratio is 114.11. In terms of profitability, HAE's ROE is +0.11%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, HAE is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for HAE.Check AXGN's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, UFPT has a market cap of 2.3B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while UFPT trades at $299.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas UFPT's P/E ratio is 30.56. In terms of profitability, HAE's ROE is +0.11%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, HAE is less volatile compared to UFPT. This indicates lower risk in terms of short-term price fluctuations for HAE.Check UFPT's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas NUVA's P/E ratio is 75.00. In terms of profitability, HAE's ROE is +0.11%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, HAE is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for HAE.Check NUVA's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, INSP has a market cap of 2B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while INSP trades at $70.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas INSP's P/E ratio is 30.84. In terms of profitability, HAE's ROE is +0.11%, compared to INSP's ROE of +0.18%. Regarding short-term risk, HAE is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for HAE.Check INSP's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, ESTA has a market cap of 1.9B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while ESTA trades at $65.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas ESTA's P/E ratio is -51.86. In terms of profitability, HAE's ROE is +0.11%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, HAE is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for HAE.Check ESTA's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, NVCR has a market cap of 1.8B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while NVCR trades at $15.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas NVCR's P/E ratio is -12.18. In terms of profitability, HAE's ROE is +0.11%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, HAE is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for HAE.Check NVCR's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, ATEC has a market cap of 1.5B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while ATEC trades at $10.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas ATEC's P/E ratio is -167.50. In terms of profitability, HAE's ROE is +0.11%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, HAE is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for HAE.Check ATEC's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, CNMD has a market cap of 1.4B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while CNMD trades at $46.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas CNMD's P/E ratio is 10.20. In terms of profitability, HAE's ROE is +0.11%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, HAE is less volatile compared to CNMD. This indicates lower risk in terms of short-term price fluctuations for HAE.Check CNMD's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas HSKA's P/E ratio is -62.49. In terms of profitability, HAE's ROE is +0.11%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, HAE is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for HAE.Check HSKA's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while IART trades at $16.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas IART's P/E ratio is 6.89. In terms of profitability, HAE's ROE is +0.11%, compared to IART's ROE of -0.01%. Regarding short-term risk, HAE is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for HAE.Check IART's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while AVNS trades at $24.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas AVNS's P/E ratio is 27.77. In terms of profitability, HAE's ROE is +0.11%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, HAE is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for HAE.Check AVNS's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while TNDM trades at $16.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas TNDM's P/E ratio is -17.66. In terms of profitability, HAE's ROE is +0.11%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, HAE is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for HAE.Check TNDM's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas SILK's P/E ratio is -18.96. In terms of profitability, HAE's ROE is +0.11%, compared to SILK's ROE of -0.35%. Regarding short-term risk, HAE is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for HAE.Check SILK's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while AORT trades at $22.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas AORT's P/E ratio is 38.23. In terms of profitability, HAE's ROE is +0.11%, compared to AORT's ROE of -0.01%. Regarding short-term risk, HAE is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for HAE.Check AORT's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while IRMD trades at $86.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas IRMD's P/E ratio is 43.55. In terms of profitability, HAE's ROE is +0.11%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, HAE is less volatile compared to IRMD. This indicates lower risk in terms of short-term price fluctuations for HAE.Check IRMD's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas FNA's P/E ratio is -19.83. In terms of profitability, HAE's ROE is +0.11%, compared to FNA's ROE of -0.35%. Regarding short-term risk, HAE is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for HAE.Check FNA's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, ENOV has a market cap of 1B. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while ENOV trades at $18.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas ENOV's P/E ratio is 5.20. In terms of profitability, HAE's ROE is +0.11%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, HAE is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for HAE.Check ENOV's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, PRCT has a market cap of 981.9M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while PRCT trades at $17.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas PRCT's P/E ratio is -8.89. In terms of profitability, HAE's ROE is +0.11%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, HAE is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for HAE.Check PRCT's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, LMRI has a market cap of 974.7M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while LMRI trades at $10.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas LMRI's P/E ratio is -19.74. In terms of profitability, HAE's ROE is +0.11%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, HAE is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for HAE.Check LMRI's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, BVS has a market cap of 949.8M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while BVS trades at $14.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas BVS's P/E ratio is 18.45. In terms of profitability, HAE's ROE is +0.11%, compared to BVS's ROE of +0.28%. Regarding short-term risk, HAE is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for HAE.Check BVS's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, CBLL has a market cap of 930M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while CBLL trades at $24.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas CBLL's P/E ratio is -13.93. In terms of profitability, HAE's ROE is +0.11%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, HAE is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for HAE.Check CBLL's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, BBNX has a market cap of 923.2M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while BBNX trades at $20.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas BBNX's P/E ratio is -12.44. In terms of profitability, HAE's ROE is +0.11%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, HAE is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for HAE.Check BBNX's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas CSII's P/E ratio is -20.83. In terms of profitability, HAE's ROE is +0.11%, compared to CSII's ROE of -0.14%. Regarding short-term risk, HAE is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for HAE.Check CSII's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, SIBN has a market cap of 832M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while SIBN trades at $18.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas SIBN's P/E ratio is -55.18. In terms of profitability, HAE's ROE is +0.11%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, HAE is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for HAE.Check SIBN's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, INMD has a market cap of 816.5M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while INMD trades at $14.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas INMD's P/E ratio is 9.86. In terms of profitability, HAE's ROE is +0.11%, compared to INMD's ROE of +0.12%. Regarding short-term risk, HAE is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for HAE.Check INMD's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, VREX has a market cap of 777.2M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while VREX trades at $18.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas VREX's P/E ratio is 19.43. In terms of profitability, HAE's ROE is +0.11%, compared to VREX's ROE of +0.05%. Regarding short-term risk, HAE is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for HAE.Check VREX's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, AHCO has a market cap of 768.7M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while AHCO trades at $5.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas AHCO's P/E ratio is 11.53. In terms of profitability, HAE's ROE is +0.11%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, HAE is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for HAE.Check AHCO's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, AVR has a market cap of 752.6M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while AVR trades at $7.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas AVR's P/E ratio is -3.99. In terms of profitability, HAE's ROE is +0.11%, compared to AVR's ROE of -0.78%. Regarding short-term risk, HAE is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for HAE.Check AVR's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, CTKB has a market cap of 741.3M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while CTKB trades at $5.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas CTKB's P/E ratio is -30.41. In terms of profitability, HAE's ROE is +0.11%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, HAE is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for HAE.Check CTKB's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas SRDX's P/E ratio is -34.66. In terms of profitability, HAE's ROE is +0.11%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, HAE is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for HAE.Check SRDX's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, KIDS has a market cap of 580M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while KIDS trades at $22.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas KIDS's P/E ratio is -19.14. In terms of profitability, HAE's ROE is +0.11%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, HAE is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for HAE.Check KIDS's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas APEN's P/E ratio is -9.43. In terms of profitability, HAE's ROE is +0.11%, compared to APEN's ROE of -0.85%. Regarding short-term risk, HAE is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for HAE.Check APEN's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, SSII has a market cap of 578.4M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while SSII trades at $2.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas SSII's P/E ratio is -48.17. In terms of profitability, HAE's ROE is +0.11%, compared to SSII's ROE of -0.27%. Regarding short-term risk, HAE is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for HAE.Check SSII's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, DCTH has a market cap of 545.8M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while DCTH trades at $15.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas DCTH's P/E ratio is 1581.00. In terms of profitability, HAE's ROE is +0.11%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, HAE is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for HAE.Check DCTH's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, HAE's ROE is +0.11%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, HAE is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for HAE.Check ZIMV's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, PACB has a market cap of 531.1M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while PACB trades at $1.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas PACB's P/E ratio is -4.17. In terms of profitability, HAE's ROE is +0.11%, compared to PACB's ROE of -49.62%. Regarding short-term risk, HAE is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for HAE.Check PACB's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, TCMD has a market cap of 514.7M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while TCMD trades at $22.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas TCMD's P/E ratio is 21.13. In terms of profitability, HAE's ROE is +0.11%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, HAE is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for HAE.Check TCMD's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, SGHT has a market cap of 504.4M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while SGHT trades at $9.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas SGHT's P/E ratio is -16.55. In terms of profitability, HAE's ROE is +0.11%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, HAE is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for HAE.Check SGHT's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, CERS has a market cap of 493.7M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while CERS trades at $2.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas CERS's P/E ratio is -81.40. In terms of profitability, HAE's ROE is +0.11%, compared to CERS's ROE of -0.10%. Regarding short-term risk, HAE is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for HAE.Check CERS's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, NPCE has a market cap of 482.4M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while NPCE trades at $14.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas NPCE's P/E ratio is -24.82. In terms of profitability, HAE's ROE is +0.11%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, HAE is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for HAE.Check NPCE's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, CLPT has a market cap of 459.1M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while CLPT trades at $15.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas CLPT's P/E ratio is -12.97. In terms of profitability, HAE's ROE is +0.11%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, HAE is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for HAE.Check CLPT's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, SENS has a market cap of 411.3M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while SENS trades at $9.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas SENS's P/E ratio is -4.41. In terms of profitability, HAE's ROE is +0.11%, compared to SENS's ROE of -1.66%. Regarding short-term risk, HAE is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for HAE.Check SENS's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, OFIX has a market cap of 397.7M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while OFIX trades at $9.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas OFIX's P/E ratio is -6.41. In terms of profitability, HAE's ROE is +0.11%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, HAE is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for HAE.Check OFIX's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, CV has a market cap of 345.7M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while CV trades at $6.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas CV's P/E ratio is -10.98. In terms of profitability, HAE's ROE is +0.11%, compared to CV's ROE of -1.78%. Regarding short-term risk, HAE is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for HAE.Check CV's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas SMLR's P/E ratio is 3.92. In terms of profitability, HAE's ROE is +0.11%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, HAE is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for HAE.Check SMLR's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, TMCI has a market cap of 290.6M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while TMCI trades at $4.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas TMCI's P/E ratio is -4.77. In terms of profitability, HAE's ROE is +0.11%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, HAE is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for HAE.Check TMCI's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, RCEL has a market cap of 289.9M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while RCEL trades at $11.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas RCEL's P/E ratio is -8.10. In terms of profitability, HAE's ROE is +0.11%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, HAE is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for HAE.Check RCEL's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, CATX has a market cap of 286.3M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while CATX trades at $2.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas CATX's P/E ratio is -1.89. In terms of profitability, HAE's ROE is +0.11%, compared to CATX's ROE of -0.42%. Regarding short-term risk, HAE is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for HAE.Check CATX's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, TLSI has a market cap of 270.3M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while TLSI trades at $4.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas TLSI's P/E ratio is -2.61. In terms of profitability, HAE's ROE is +0.11%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, HAE is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for HAE.Check TLSI's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, INFU has a market cap of 259.4M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while INFU trades at $12.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas INFU's P/E ratio is 31.35. In terms of profitability, HAE's ROE is +0.11%, compared to INFU's ROE of +0.15%. Regarding short-term risk, HAE is less volatile compared to INFU. This indicates lower risk in terms of short-term price fluctuations for HAE.Check INFU's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas MGRM's P/E ratio is -12.00. In terms of profitability, HAE's ROE is +0.11%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, HAE is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for HAE.Check MGRM's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, ELMD has a market cap of 233.3M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while ELMD trades at $28.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas ELMD's P/E ratio is 21.51. In terms of profitability, HAE's ROE is +0.11%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, HAE is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for HAE.Check ELMD's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas NVRO's P/E ratio is -1.91. In terms of profitability, HAE's ROE is +0.11%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, HAE is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for HAE.Check NVRO's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, PROF has a market cap of 215.1M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while PROF trades at $5.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas PROF's P/E ratio is -6.04. In terms of profitability, HAE's ROE is +0.11%, compared to PROF's ROE of -0.56%. Regarding short-term risk, HAE is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for HAE.Check PROF's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, RXST has a market cap of 193.3M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while RXST trades at $4.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas RXST's P/E ratio is -4.13. In terms of profitability, HAE's ROE is +0.11%, compared to RXST's ROE of -0.17%. Regarding short-term risk, HAE is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for HAE.Check RXST's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas BSGM's P/E ratio is -5.81. In terms of profitability, HAE's ROE is +0.11%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, HAE is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for HAE.Check BSGM's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas MDGS's P/E ratio is -0.27. In terms of profitability, HAE's ROE is +0.11%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, HAE is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for HAE.Check MDGS's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, STIM has a market cap of 177.8M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while STIM trades at $2.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas STIM's P/E ratio is -5.81. In terms of profitability, HAE's ROE is +0.11%, compared to STIM's ROE of -1.51%. Regarding short-term risk, HAE is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for HAE.Check STIM's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, FOCL has a market cap of 169.8M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while FOCL trades at $4.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas FOCL's P/E ratio is -4.38. In terms of profitability, HAE's ROE is +0.11%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, HAE is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for HAE.Check FOCL's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, QTRX has a market cap of 165.8M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while QTRX trades at $3.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas QTRX's P/E ratio is -1.39. In terms of profitability, HAE's ROE is +0.11%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, HAE is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for HAE.Check QTRX's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while QIPT trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas QIPT's P/E ratio is -15.87. In terms of profitability, HAE's ROE is +0.11%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, HAE is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for HAE.Check QIPT's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, QSI has a market cap of 157.3M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while QSI trades at $0.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas QSI's P/E ratio is -1.73. In terms of profitability, HAE's ROE is +0.11%, compared to QSI's ROE of -0.47%. Regarding short-term risk, HAE is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for HAE.Check QSI's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, LUCD has a market cap of 153.7M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while LUCD trades at $0.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas LUCD's P/E ratio is -2.18. In terms of profitability, HAE's ROE is +0.11%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, HAE is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for HAE.Check LUCD's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, INGN has a market cap of 147.3M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while INGN trades at $5.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas INGN's P/E ratio is -5.98. In terms of profitability, HAE's ROE is +0.11%, compared to INGN's ROE of -0.13%. Regarding short-term risk, HAE is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for HAE.Check INGN's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while ICAD trades at $3.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas ICAD's P/E ratio is -20.37. In terms of profitability, HAE's ROE is +0.11%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, HAE is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for HAE.Check ICAD's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, ECOR has a market cap of 99.4M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while ECOR trades at $11.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas ECOR's P/E ratio is -6.57. In terms of profitability, HAE's ROE is +0.11%, compared to ECOR's ROE of +5.25%. Regarding short-term risk, HAE is less volatile compared to ECOR. This indicates lower risk in terms of short-term price fluctuations for HAE.Check ECOR's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while HJLI trades at $10.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas HJLI's P/E ratio is N/A. In terms of profitability, HAE's ROE is +0.11%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, HAE is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for HAE.Check HJLI's competition here

Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HAE stands at 4.8B. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, HAE is priced at $105.79 on the NYSE, while ASXC trades at $0.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HAE currently has a P/E ratio of 21.13, whereas ASXC's P/E ratio is -1.12. In terms of profitability, HAE's ROE is +0.11%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, HAE is more volatile compared to ASXC. This indicates higher risk in terms of short-term price fluctuations for HAE.Check ASXC's competition here